Deferasirox is an iron chelator commonly used to treat iron-overload disease. Deferasirox also displays both neuroprotective and chemotherapeutic benefit as well. This compound exhibits neuroprotective activity in both in vitro and in vivo models of stroke/ischemia conditions. In vitro, deferasirox increases expression of metastasis suppressing genes, p21, caspase-3, and PARP and decreases levels of cyclin D1 and activity of NF-κB. The ability of deferasirox to inhibit iron uptake decreases tumor growth in animal models of cancer.